SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Translate Bio Resumes Enrollment And Dosing In Phase 1/2 Clinical Trial Of MRT5005 In Cystic Fibrosis

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat

· 09/08/2020 07:34

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (NASDAQ:TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that enrollment and dosing in its Phase 1/2 clinical trial for MRT5005 in cystic fibrosis (CF) has resumed, with multiple clinical sites being open for enrollment. In March 2020, the Company had announced a pause to enrollment and dosing in the clinical trial in response to the COVID-19 pandemic. The Company plans to provide updated timing on the expected interim data readout of the additional single-ascending dose (SAD) group and the multiple-ascending dose (MAD) portion of the clinical trial at a later date.
 

"We are pleased that enrollment and dosing in the Phase 1/2 clinical trial of MRT5005 has resumed. Our top priority remains the safety of the patients and the health care providers involved with the study, and we continue to work together with the clinical trial sites as we navigate these unprecedented circumstances," said Dr. Ann Barbier, Chief Medical Officer of Translate Bio.